title: Study on the release of fenofibrate nanosuspension in vitro and its correlation with in situ intestinal and in vivo absorption kinetics in rats.
abstract: As an oral delivery carrier for poorly water soluble drugs, the nanosuspension was prepared by melt emulsification method combined with high-pressure homogenization. The objective of this study was to clarify the absorption mechanism in rats of fenofibrate nanosuspension using the model of in situ gut perfusion. The release rate of drug from nanosuspension was fast which about 70% of the drug would be released within 5 minutes. The absorption of fenofibrate nanosuspension in the gastrointestinal (GI) tract was studied by the in situ closed loop method in rats. It was found that the absorption process in intestine was first-process with passive diffusion mechanism, and the whole intestine was the major segment for the drug absorption. Additionally, GI absorption in situ studies indicated that the fenofibrate nanosuspension had great success in regard to enhancement of intestinal absorption compared to the fenofibrate suspension of coarse powder. The pharmacokinetic characteristics were studied in rats after oral administration of fenofibrate nanosuspension or suspension at the dosage of 27 mg/kg. The plasma concentration-time curve was fitted to the one-compartment model. The correlation between in vitro dissolution (P), in situ intestinal absorption (F) and in vivo absorption (Fa) in rats was investigated with the results as follows: Fa = 6.2061P-456.38(r = 0.9559), F = 3.6911P-2.2169(r = 0.970), F = 0.5095P + 44.189(r = 0.9609). The highest level A could be obtained from the in vitro--in vivo correlation (IVIVC) between dissolution percentage and intestinal absorption of the fenofibrate nanosuspension in rats. Consequently, the in situ intestinal perfusion model could be used to predict the in vivo pharmacokinetic characteristics in rats.
authors.affiliation: College of Pharmacy and.
authors.forename: Yuanlong
authors.initials: Y
authors.lastname: Xu
authors.forename: Yonglu
authors.initials: Y
authors.lastname: Wang
authors.forename: Xue Ming
authors.initials: XM
authors.lastname: Li
authors.forename: Qinqin
authors.initials: Q
authors.lastname: Huang
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Ran
authors.initials: R
authors.lastname: Liu
authors.forename: BaoAn
authors.initials: B
authors.lastname: Chen
authors.forename: Ping
authors.initials: P
authors.lastname: Wei
mesh_terms: D000284:Administration, Oral; D000818:Animals; D055598:Chemical Phenomena; D003106:Colon / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D065546:Drug Liberation; D011345:Fenofibrate / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007408:Intestinal Absorption; D007421:Intestine, Small / Q000378:metabolism; D008297:Male; D053758:Nanoparticles / Q000737:chemistry*; D017207:Rats, Sprague-Dawley; D013535:Suspensions
chemical_list: D004337:Drug Carriers; D000960:Hypolipidemic Agents; D013535:Suspensions; D011345:Fenofibrate
keywords: Absorption mechanism; fenofibrate nanosuspension; gastrointestinal; in situ intestinal perfusion model; in vitro–in vivo correlations